Phase I/II clinical trial for therapeutic HB vaccine containing HBsAg and HBcAg

Phase I/II clinical trial for therapeutic HB vaccine containing HBsAg and HBcAg - Clinical trial for therapeutic HB vaccine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027442

Enrollment

120

Registered

2017-05-22

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

HBV patients with inactive carrier or under nucleotide analogues treatment will receive therapeutic vaccine 10 times every two weeks intranasally.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HBV inactive carrier chronic hepatitis B patients treating with nucleotide analogue

Exclusion criteria

Exclusion criteria: severe complication malignancy taking immunosuppresive agents

Design outcomes

Primary

Measure	Time frame
Safety: frequency and degree of adverse events	—

Secondary

Measure	Time frame
Efficacy: HBV-DNA reduction	—

Countries

Japan

Contacts

Public ContactOsamu Yoshida

Ehime University Graduate School of Medicine Department of Gastroenterology and Metabology

yoshidao@m.ehime-u.ac.jp089-960-5308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026